Follow The Filings

FRPT Freshpet Inc.

Consumer Staples, filed as FRESHPET INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 8.8%
  • $41M
  • 1 new 1 exit

In 2026 Q2 Glenn Welling opened a position in Freshpet, while Lee Ainslie sold out.

Who owns this now

Largest portfolio weights among holders, up to 8.8% (Glenn Welling, Engaged Capital). Not free-float ownership.

  1. Glenn Welling New 8.8%
  2. Davidson Kempner Capital Mana... 0.15%

Who owns FRPT

Sorted by value, long equity only, as of 2026 Q2.

History
Glenn Welling, Engaged Capital 8.8% New 8.8% 484,741 $29M History
Davidson Kempner Capital Management 0.15% Hold 211,400 $12M History
Lee Ainslie, Maverick Capital exited 2026 Q2 Last 2026 Q1 0.02% Exit −0.02% 34,509 $2M History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FRPT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FRPT insider trades
  • $573K bought by 6 insiders
  • $3.8M sold by 1 insider outside a trading plan
  • $33.2M sold by 1 insider under 10b5-1 plans
  1. Walter N. George Director
    Buy
    $65K 1,000 shares at $64.92 +2% to stake
    Traded Sep 14 Filed Sep 16
    ↗
  2. William B. Cyr CEO
    Planned sale
    $3M 39,664 shares at $74.72
    Traded Aug 26 Filed Aug 28
    ↗
  3. William B. Cyr CEO
    Planned sale
    $6.6M 87,905 shares at $74.88
    Traded Aug 21–24 Filed Aug 25
    ↗
  4. William B. Cyr CEO
    Planned sale
    $3.3M 44,078 shares at $74.72
    Traded Aug 19 Filed Aug 21
    ↗
  5. William B. Cyr CEO
    Planned sale
    $3.2M 44,067 shares at $72.83
    Traded Aug 17 Filed Aug 19
    ↗
  6. William B. Cyr CEO
    Planned sale
    $3.2M 44,069 shares at $72.90
    Traded Aug 14 Filed Aug 18
    ↗
  7. William B. Cyr CEO
    Planned sale
    $2.4M 46,814 shares at $51.04
    Traded May 22 Filed May 27
    ↗
  8. William B. Cyr CEO
    Planned sale
    $2.3M 47,582 shares at $47.88
    Traded May 20 Filed May 22
    ↗
  9. Daryl G Brewster Director
    Buy
    $10K 211 shares at $47.52 +0.4% to stake
    Traded May 20 Filed May 22
    ↗
  10. Craig D. Steeneck Director
    Buy
    $96K 2,000 shares at $47.83 +5.6% to stake
    Traded May 20 Filed May 22
    ↗
  11. Timothy R McLevish Director
    Buy
    $146K 3,000 shares at $48.67 +8.1% to stake
    Traded May 18 Filed May 20
    ↗
  12. David Biegger Director
    Buy
    $49K 1,000 shares at $49.14 +13% to stake
    Traded May 18 Filed May 20
    ↗
  13. Jacki Sue Kelley Director
    Buy
    $48K 1,000 shares at $48.05 +7.4% to stake
    Traded May 18 Filed May 20
    ↗
  14. William B. Cyr CEO
    Planned sale
    $4.6M 94,364 shares at $49.15
    Traded May 15–18 Filed May 19
    ↗
  15. William B. Cyr CEO
    Planned sale
    $2.3M 46,818 shares at $48.98
    Traded May 13 Filed May 15
    ↗

Also filed in the last 12 months, not counted as buying or selling: 52 option exercises, 21 stock grants, and 17 share withholdings for taxes.

Congress

1 member of Congress traded FRPT in the last three years: 2 buys and 2 sales.

All Congress trades
  1. Markwayne Mullin R-OK Sell $15K–$50K Dec 18, 2024 filed Dec 31, 2024
  2. Markwayne Mullin R-OKSpouse Sell $15K–$50K Dec 18, 2024 filed Dec 31, 2024
  3. Markwayne Mullin R-OK Buy $1K–$15K Jan 4, 2024 filed Jan 26, 2024
  4. Markwayne Mullin R-OKSpouse Buy $1K–$15K Jan 4, 2024 filed Jan 26, 2024

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.767B $0.975B $1.1B
Gross profit $250.87M $395.96M $449.63M
Gross margin * 32.7% 40.6% 40.8%
Net income -$33.61M $46.92M $139.14M
Net margin * -4.4% 4.8% 12.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $427.32M $437M $435.71M
Total non-current assets * $1.04B $1.14B $1.34B
Total assets $1.46B $1.57B $1.78B
Total current liabilities $89.22M $98.87M $78.6M
Total non-current liabilities * $421.74M $420.65M $490.52M
Total equity $0.953B $1.06B $1.21B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $75.94M $154.29M $160.56M
Cash from investing -$239.09M -$187.09M -$148.18M
Cash from financing $327.29M $4.57M -$3.04M
Net change in cash * $164.14M -$28.24M $9.34M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.